Baxter Healthcare Corporation, a pharmaceutical and biotechnology company based in Deerfield, IL, announced collaborative research agreements intended to develop a longer-lasting version of Baxter’s recombinant factor VIII product Advate®.
Nektar Therapeutics of San Carlos, CA will apply its PEGylation technology to Advate®, in order to extend the half-life of the product. This innovation would potentially result in fewer infusions for hemophilia patients. “Baxter continues to apply its own scientific resources and leverage strategic collaborations with biotechnology companies, in order to improve hemophilia therapy,” said Norbert Riedel, PhD, chief scientific officer at Baxter.
Lipoxen Technologies, based in London, England has agreed to employ its PolyXen technology to develop modified proteins that will help Baxter improve hemophilia therapies. Dr. Riedel added, “this latest agreement with Lipoxen reflects our focus on advancing and evaluating promising technologies aimed at extending the duration of action of blood clotting factors.”
Source: Baxter news release dated September 29, 2005